logo
Home Register FAQ Members List Calendar New Posts Search

Go Back   Forums > Stock picks and trading strategies

Reply
 
Thread Tools Display Modes
  #1  
Old 06-20-2017,
3susazmeqvexvbs4 3susazmeqvexvbs4 is offline
Junior Member
 
Join Date: May 2017
Posts: 0
Default AQSZF (MC $10 M) 2 Marketed Drugs & 3 Drugs nearing Approval

This completely undiscovered low float is definitely one of the cheapest Biotech Gem you can get at this time. This Stock has 10 bagger Potential easily with all the Big Drugs close to Market entry .Aequus has begun to Market 2 Drugs called Vistitan (Glaucoma) and Tacrolimus IR (Transplant) in first half 2016 in Canada and they got the Canadian rights for the Epilepsy drugs Trokendi XR and Oxtellar XR from Supernus Pharma (SUPN) earlier this year , NDS submission for Approval is expected in early 2017 .Peak sales for these 4 drugs is between $40-45 Million according to Management which is HUGE for this microcap stock with a ridiculous market cap of $10 Million .Management alone holding over 16 Million shares Ceo just bought 840k shares at 0.30 a few days ago .GLTA
Reply With Quote
  #2  
Old 06-21-2017,
27FYYSUPXz 27FYYSUPXz is offline
 
Join Date: Apr 2017
Posts: 0
Default

Patch Positive Proof of Concept Clinical Data for Once-Weekly Transdermal Aripiprazole Patch: Aequus’ once-weekly transdermal aripiprazole program is being developed for the treatment of certain psychiatric disorders. In the first half of 2016, Aequus announced positive results from an initial Proof of Concept clinical study, which suggested the current formulation may provide sustained, seven-day delivery of therapeutic doses of aripiprazole. Aequus is preparing for the follow-on, multi-dose bioavailability study expected to be initiated in the second half of 2016. Aequus has also expanded the patent portfolio for this program, with a patent issued / allowed in five major countries or regions, including the US, Russia, Mexico, Japan and Australia, and pending in multiple additional territories. Aequus owns worldwide rights to the formulation described in the issued patent, and will look to partner commercial rights in markets outside of Canada as the program continues to advance.
Reply With Quote
  #3  
Old 06-23-2017,
58695236 58695236 is offline
 
Join Date: May 2017
Posts: 0
Default

The share price has been a negative surprise over the last few months. The business is going well, sales are growing and we expect additional commercial deals for revenue generating products to be announced this quarter. We also are about to start the second clinical trial for our transdermal Abilify product this month and our partner Corium has begun work on the next two transdermal programs. We have a lot of confidence in the business model and expect big things in 2017. Tax loss selling hurt the share price in December but in general the share price has been weaker than I expected. I personally bought 1million shares in 2016 and plan to buy more once I come out of a trading blackout. Our goal is to be profitable before the end of 2017 which at that point will remove the requirement for going to investors for financings.
Reply With Quote
  #4  
Old 06-23-2017,
63sOlZdAR2 63sOlZdAR2 is offline
Junior Member
 
Join Date: May 2017
Posts: 0
Default

There is a lot of big news on the way which will drive the sp much higher again like the AQS1301 topline results which are imminent(this month) and new Product acquisitions .The Stock is brutally undervalued with a laughable market cap of just US$15 million .
Reply With Quote
Reply

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is On

Forum Jump


All times are GMT. The time now is .